US20060134147A1 - Cosmetic compositions having carnitine creatinate and methods for using - Google Patents
Cosmetic compositions having carnitine creatinate and methods for using Download PDFInfo
- Publication number
- US20060134147A1 US20060134147A1 US11/018,901 US1890104A US2006134147A1 US 20060134147 A1 US20060134147 A1 US 20060134147A1 US 1890104 A US1890104 A US 1890104A US 2006134147 A1 US2006134147 A1 US 2006134147A1
- Authority
- US
- United States
- Prior art keywords
- composition
- skin
- present
- carnitine creatinate
- carnitine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(=O)CN(C)c(n)n.[CH2+]N(C)(C)CC(O)CC(=O)O Chemical compound CC(=O)CN(C)c(n)n.[CH2+]N(C)(C)CC(O)CC(=O)O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Definitions
- the present invention relates to a topical composition that improves the aesthetic appearance of skin.
- the present invention also relates to a topical composition that inhibits induced lipid synthesis in skin.
- the present invention further relates to a topical composition that inhibits the formation of cellulite in skin.
- Fat may build up underneath the surface of the skin due to induced lipid synthesis in the adipose layer of the skin.
- the buildup may take the form of a multiplicity of small but recognizable pockets of fat underneath the surface of the skin. Such buildup is commonly referred to as cellulite.
- Cellulite may impart an unnatural appearance to the skin. Skin can appear lumpy and discontinuous.
- topical composition that inhibited induced lipid synthesis in the skin. It would also be desirable to have a topical composition that inhibited the formation of cellulite in skin. It would further be desirable to have a topical composition that improves the aesthetic appearance of skin.
- the active ingredient in the composition is carnitine creatinate.
- Carnitine creatinate is represented by the following structure:
- X is an integer of 0 to about 5.
- Carnitine creatinate is a salt of the acid-base reaction between carnitine and creatine.
- Carnitine creatinate is available commercially as a 100% active from American International Chemical, Inc.
- Carnitine creatinate is further described in U.S. Pat. No. 5,994,581, which is incorporated herein by reference in its entirety.
- the carnitine creatinate is present in an amount effective to improve the aesthetic appearance of skin.
- the carnitine creatinate may also be present in an amount effective to inhibit induced lipid synthesis.
- the carnitine creatinate may further be present in an amount effective to inhibit formation of cellulite.
- the carnitine creatinate is present at about 0.01 wt % to about 25 wt % based on the total weight of the composition. More preferably, the carnitine creatinate is present at about 0.05 wt % to about 10 wt %. Most preferably, the carnitine creatinate is present at about 0.1 wt % to about 5 wt %.
- compositions useful in the present method have a vehicle that is pharmaceutically or cosmetically acceptable.
- vehicles include, but are not limited to, one or more lower alcohols, fatty alcohols, fatty ethers, fatty esters, isododecane, polyols, glycols, liposomes, laminar lipid materials, water, or any combinations thereof.
- the composition may take any product form known in the art.
- Useful forms include, but are not limited to, aerosol spray, cream, lotion, gel, foam, ointment, mask, mousse, patch, powder, pump spray, stick, tape, towelette, and pomade.
- Liquid forms of the composition may be any type, such as a solution, suspension, dispersion, or emulsion.
- Useful emulsion forms include oil-in-water, water-in-oil, silicone-in-water, water-in-silicone, and triple emulsions.
- the composition may be aqueous or anhydrous.
- Compositions may also include one or more of the following optional ingredients: amino acids, anesthetics, anti-acne agents, anti-allergenics, antifungals, antimicrobials, anti-inflammatory agents, anti-irritants, antioxidants, antiseptics, antivirals, chelating agents, colorants, depigmenting agents, emollients, emulsifiers, exfoliants, for example, ⁇ -hydroxy acids such as lactic acid and glycolic acid, ⁇ -hydroxy acids, sugar acids, oxa acids, and oxa diacids, film formers, fragrances, humectants, hyper- and hypopigmenting agents, self-tanning agents, insect repellents, lubricants, moisturizers, peptides, pharmaceutical agents, photostabilizing agents, preservatives, retinoids, vitamins and vitamin derivatives such as niacin (nicotinic acid) and ascorbic acid and its derivatives, salicylic acid, skin protectants, skin penetration enhance
- composition is also useful in preventing, ameliorating or treating acne; preventing, ameliorating or treating oily skin; preventing, ameliorating or treating oily hair; preventing, ameliorating or treating oily scalp; preventing, ameliorating or treating skin blemishes; preventing, ameliorating or treating skin breakouts; and improving skin texture.
- the composition may be applied to the skin one or more times per day as needed or desired. If desired, the composition may be applied twice or more per day. Generally, the composition is applied as often as needed to impart and maintain a desirable aesthetic appearance to the skin or to maintain a skin appearance substantially free of cellulite. Typically, beneficial results are observed following daily application of the topical composition for a period of one week, preferably two weeks, especially four weeks, and most preferably after eight weeks.
- hydrogel patch that incorporates the carnitine creatinate, which is admixed with the hydrogel base.
- the patch can be affixed to an area of the skin of the user in need of fat reduction, for example, the inner thigh of the user.
- the patch is applied to the skin for a period of time effective for treatment, e.g., four or more hours per day for one day or two days, after which time the patch is removed.
- a second patch is then affixed, and the process is repeated over an extended period of time, i.e., about four weeks, preferably eight weeks, and most preferably 12 weeks.
- compositions of the present invention in gel (Composition A) and cream (Composition B) forms are prepared. Ingredients of the compositions are set forth in Table 1 below. TABLE 1 Composition A (Gel) Composition B (Cream) Ingredients (Wt. %) (Wt. %) Carnitine creatinate 0.1-5.0 0.1-5.0 Glycerin 3.0-5.0 3.0-7.0 Propylene glycol 1.0-3.0 Thickener 0.5-1.0 0.5-1.0 Ethanol 0.1-5.0 Emulsifier 1.0-10.0 Oil 1.0-10.0 Ester 1.0-10.0 Wax 0.1-5.0 Silicone oil 0.1-5.0 Powder 0.0-2.0 Preservative 0.1-0.7 0.1-0.7 Water QS 100.0% QS 100.0% QS 100.0%
- Composition A is prepared by admixing the ingredients together at 25° C. to 30° C. and allowing the mixture to thicken to form a gel.
- Composition B is made by forming an aqueous phase premix of water and water soluble components, which premix is heated to 80° C. and an oil phase premix of oil, silicone, wax, ester components, and an emulsifier, which premix is heated to 80° C. The oil phase is then blended with the water phase, and cooled to room temperature.
- Compositions A and B are applied to areas of the body in need of fat reduction, in particular to the arms, thighs, and buttocks. Compositions A and B are applied daily for a period of time, typically about eight weeks, to effect an improvement in the appearance of the skin, in particular, an observable reduction in fat density, circumference and the unwanted appearance of cellulite.
- a hydrogel patch is prepared by premixing the carnitine creatinate and the hydrogel base.
- the patch is affixed to the area of the skin of the user in need of fat reduction, for example, the inner thigh of the user.
- the patch is removed after 1 to 2 days and a second patch is then affixed. The process is then repeated over a period of eight weeks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There is a topical composition having carnitine creatinate and a cosmetically acceptable vehicle. There is also provided a method for improving the aesthetic appearance of skin. There is also provided a method for inhibiting the induced lipid synthesis in skin. There is also provided a method for inhibiting the formation of cellulite in skin.
Description
- 1. Field of the Invention
- The present invention relates to a topical composition that improves the aesthetic appearance of skin. The present invention also relates to a topical composition that inhibits induced lipid synthesis in skin. The present invention further relates to a topical composition that inhibits the formation of cellulite in skin.
- 2. Description of the Related Art
- Fat may build up underneath the surface of the skin due to induced lipid synthesis in the adipose layer of the skin. The buildup may take the form of a multiplicity of small but recognizable pockets of fat underneath the surface of the skin. Such buildup is commonly referred to as cellulite. Cellulite may impart an unnatural appearance to the skin. Skin can appear lumpy and discontinuous.
- It would be desirable to have a topical composition that inhibited induced lipid synthesis in the skin. It would also be desirable to have a topical composition that inhibited the formation of cellulite in skin. It would further be desirable to have a topical composition that improves the aesthetic appearance of skin.
- It is an object of the present invention to provide a topical composition that improves the aesthetic appearance of skin.
- It is another object of the present invention to provide a topical composition that inhibits the induced lipid synthesis in skin.
- It is still another object of the present invention to provide a topical composition that inhibits the formation of cellulite in skin.
- It is yet another object of the present invention to provide a topical composition having carnitine creatinate and a cosmetically acceptable vehicle.
- It is a further object of the present invention to provide a method for improving the aesthetic appearance of skin by providing a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate that is topically applied to the skin.
- It is yet a further object of the present invention to provide a method for inhibiting induced lipid synthesis in skin by providing a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate that is topically applied to the skin.
- It is still yet a further object of the present invention to provide also a method for inhibiting the formation of cellulite in skin by providing a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate that is topically applied to the skin.
-
- wherein X is an integer of 0 to about 5.
- Carnitine creatinate is a salt of the acid-base reaction between carnitine and creatine. Carnitine creatinate is available commercially as a 100% active from American International Chemical, Inc. Carnitine creatinate is further described in U.S. Pat. No. 5,994,581, which is incorporated herein by reference in its entirety.
- The carnitine creatinate is present in an amount effective to improve the aesthetic appearance of skin. The carnitine creatinate may also be present in an amount effective to inhibit induced lipid synthesis. The carnitine creatinate may further be present in an amount effective to inhibit formation of cellulite. Preferably, the carnitine creatinate is present at about 0.01 wt % to about 25 wt % based on the total weight of the composition. More preferably, the carnitine creatinate is present at about 0.05 wt % to about 10 wt %. Most preferably, the carnitine creatinate is present at about 0.1 wt % to about 5 wt %.
- Compositions useful in the present method have a vehicle that is pharmaceutically or cosmetically acceptable. Such vehicles include, but are not limited to, one or more lower alcohols, fatty alcohols, fatty ethers, fatty esters, isododecane, polyols, glycols, liposomes, laminar lipid materials, water, or any combinations thereof.
- The composition may take any product form known in the art. Useful forms include, but are not limited to, aerosol spray, cream, lotion, gel, foam, ointment, mask, mousse, patch, powder, pump spray, stick, tape, towelette, and pomade. Liquid forms of the composition may be any type, such as a solution, suspension, dispersion, or emulsion. Useful emulsion forms include oil-in-water, water-in-oil, silicone-in-water, water-in-silicone, and triple emulsions. The composition may be aqueous or anhydrous.
- Compositions may also include one or more of the following optional ingredients: amino acids, anesthetics, anti-acne agents, anti-allergenics, antifungals, antimicrobials, anti-inflammatory agents, anti-irritants, antioxidants, antiseptics, antivirals, chelating agents, colorants, depigmenting agents, emollients, emulsifiers, exfoliants, for example, α-hydroxy acids such as lactic acid and glycolic acid, β-hydroxy acids, sugar acids, oxa acids, and oxa diacids, film formers, fragrances, humectants, hyper- and hypopigmenting agents, self-tanning agents, insect repellents, lubricants, moisturizers, peptides, pharmaceutical agents, photostabilizing agents, preservatives, retinoids, vitamins and vitamin derivatives such as niacin (nicotinic acid) and ascorbic acid and its derivatives, salicylic acid, skin protectants, skin penetration enhancers, staining agents, sunscreens, stabilizers, surfactants, thickeners, viscosity and/or rheology modifiers, or any combinations thereof.
- The composition is also useful in preventing, ameliorating or treating acne; preventing, ameliorating or treating oily skin; preventing, ameliorating or treating oily hair; preventing, ameliorating or treating oily scalp; preventing, ameliorating or treating skin blemishes; preventing, ameliorating or treating skin breakouts; and improving skin texture.
- The composition may be applied to the skin one or more times per day as needed or desired. If desired, the composition may be applied twice or more per day. Generally, the composition is applied as often as needed to impart and maintain a desirable aesthetic appearance to the skin or to maintain a skin appearance substantially free of cellulite. Typically, beneficial results are observed following daily application of the topical composition for a period of one week, preferably two weeks, especially four weeks, and most preferably after eight weeks.
- In another aspect of the invention, there is a hydrogel patch that incorporates the carnitine creatinate, which is admixed with the hydrogel base. The patch can be affixed to an area of the skin of the user in need of fat reduction, for example, the inner thigh of the user. The patch is applied to the skin for a period of time effective for treatment, e.g., four or more hours per day for one day or two days, after which time the patch is removed. A second patch is then affixed, and the process is repeated over an extended period of time, i.e., about four weeks, preferably eight weeks, and most preferably 12 weeks.
- In view of the foregoing, it is surprising that the aesthetic appearance of the skin can be improved by the topical application of the compositions of the present invention. It is further surprising that induced lipid synthesis in the skin can also be inhibited by the topical application of the compositions of the present invention. It is still further surprising that the formation of cellulite can be inhibited by such topical application.
- The following are examples of the present invention. Unless otherwise indicated, all percentages or parts are by weight.
- Compositions of the present invention in gel (Composition A) and cream (Composition B) forms are prepared. Ingredients of the compositions are set forth in Table 1 below.
TABLE 1 Composition A (Gel) Composition B (Cream) Ingredients (Wt. %) (Wt. %) Carnitine creatinate 0.1-5.0 0.1-5.0 Glycerin 3.0-5.0 3.0-7.0 Propylene glycol 1.0-3.0 Thickener 0.5-1.0 0.5-1.0 Ethanol 0.1-5.0 Emulsifier 1.0-10.0 Oil 1.0-10.0 Ester 1.0-10.0 Wax 0.1-5.0 Silicone oil 0.1-5.0 Powder 0.0-2.0 Preservative 0.1-0.7 0.1-0.7 Water QS 100.0% QS 100.0% - Composition A is prepared by admixing the ingredients together at 25° C. to 30° C. and allowing the mixture to thicken to form a gel.
- Composition B is made by forming an aqueous phase premix of water and water soluble components, which premix is heated to 80° C. and an oil phase premix of oil, silicone, wax, ester components, and an emulsifier, which premix is heated to 80° C. The oil phase is then blended with the water phase, and cooled to room temperature.
- Compositions A and B are applied to areas of the body in need of fat reduction, in particular to the arms, thighs, and buttocks. Compositions A and B are applied daily for a period of time, typically about eight weeks, to effect an improvement in the appearance of the skin, in particular, an observable reduction in fat density, circumference and the unwanted appearance of cellulite.
- A hydrogel patch is prepared by premixing the carnitine creatinate and the hydrogel base. The patch is affixed to the area of the skin of the user in need of fat reduction, for example, the inner thigh of the user. The patch is removed after 1 to 2 days and a second patch is then affixed. The process is then repeated over a period of eight weeks.
- It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances that fall within the scope of the appended claims.
Claims (18)
1. A topical composition, comprising:
carnitine creatinate; and
a cosmetically acceptable vehicle.
2. The composition of claim 1 , wherein the carnitine creatinate is present in an amount effective to improve the aesthetic appearance of skin.
3. The composition of claim 1 , wherein the carnitine creatinate is present in an amount effective to inhibit induced lipid synthesis in skin.
4. The composition of claim 1 , wherein the carnitine creatinate is present in an amount effective to inhibit cellulite formation in skin.
5. The composition of claim 1 , wherein the carnitine creatinate is present at about 0.01 wt % to about 25 wt % based on the total weight of the composition.
6. The composition of claim 1 , wherein the carnitine creatinate is present at about 0.05 wt % to about 10 wt % based on the total weight of the composition.
7. The composition of claim 1 , wherein the carnitine creatinate is present at about 0.1 wt % to about 5 wt % based on the total weight of the composition.
8. A method for improving the aesthetic appearance of skin, comprising: topically applying to the skin a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate.
9. The method of claim 8 , wherein the carnitine creatinate is present at about 0.01 wt % to about 25 wt % based on the total weight of the composition.
10. The method of claim 8 , wherein the carnitine creatinate is present at about 0.05 wt % to about 10 wt % based on the total weight of the composition.
11. The method of claim 8 , wherein the carnitine creatinate is present at about 0.1 wt % to about 5 wt % based on the total weight of the composition.
12. The method of claim 8 , wherein the vehicle has an adjuvant selected from the group consisting of one or more lower alcohols, fatty alcohols, fatty ethers, fatty esters, isododecane, polyols, glycols, liposomes, laminar lipid materials, water, and any combinations thereof.
13. The method of claim 8 , wherein the composition is in the form of a product selected from the group consisting of aerosol spray, cream, lotion, gel, foam, ointment, mask, mousse, patch, powder, pump spray, stick, tape, towelette, patch, and pomade.
14. The method of claim 8 , further comprising one or more optional ingredients selected from the group consisting of amino acids, anesthetics, anti-acne agents, anti-allergenics, antifungals, antimicrobials, anti-inflammatory agents, anti-irritants, antioxidants, antiseptics, antivirals, chelating agents, colorants, hyperpigmenting agents, self-tanning agents, emollients, emulsifiers, exfoliants, film formers, fragrances, humectants, hypopigmenting agents, insect repellents, lubricants, moisturizers, pharmaceutical agents, peptides, vitamins and vitamin derivatives, photostabilizing agents, preservatives, retinoids, skin protectants, skin penetration enhancers, staining agents, sunscreens, stabilizers, surfactants, thickeners, viscosity and/or rheology modifiers, and any combinations thereof.
15. A method for inhibiting the induced lipid synthesis in skin, comprising: topically applying to the skin a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate.
16. The method of claim 15 , wherein the carnitine creatinate is present at about 0.01 wt % to about 25 wt % based on the total weight of the composition.
17. A method for inhibiting the formation of cellulite in skin, comprising: topically applying to the skin a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate.
18. The method of claim 17 , wherein the carnitine creatinate is present at about 0.01 wt % to about 25 wt % based on the total weight of the composition.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/018,901 US20060134147A1 (en) | 2004-12-21 | 2004-12-21 | Cosmetic compositions having carnitine creatinate and methods for using |
EP05826087A EP1827360A4 (en) | 2004-12-21 | 2005-11-08 | Cosmetic compositions having carnitine creatinate and methods for using |
PCT/US2005/040480 WO2006068715A2 (en) | 2004-12-21 | 2005-11-08 | Cosmetic compositions having carnitine creatinate and methods for using |
US11/880,167 US7763655B2 (en) | 2004-12-21 | 2007-07-20 | Cosmetic compositions having carnitine creatinate and methods for using |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/018,901 US20060134147A1 (en) | 2004-12-21 | 2004-12-21 | Cosmetic compositions having carnitine creatinate and methods for using |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/880,167 Continuation US7763655B2 (en) | 2004-12-21 | 2007-07-20 | Cosmetic compositions having carnitine creatinate and methods for using |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060134147A1 true US20060134147A1 (en) | 2006-06-22 |
Family
ID=36596083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/018,901 Abandoned US20060134147A1 (en) | 2004-12-21 | 2004-12-21 | Cosmetic compositions having carnitine creatinate and methods for using |
US11/880,167 Expired - Fee Related US7763655B2 (en) | 2004-12-21 | 2007-07-20 | Cosmetic compositions having carnitine creatinate and methods for using |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/880,167 Expired - Fee Related US7763655B2 (en) | 2004-12-21 | 2007-07-20 | Cosmetic compositions having carnitine creatinate and methods for using |
Country Status (3)
Country | Link |
---|---|
US (2) | US20060134147A1 (en) |
EP (1) | EP1827360A4 (en) |
WO (1) | WO2006068715A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043312A1 (en) * | 2003-07-25 | 2005-02-24 | Shea Thomas B. | Formulations for reducing neuronal degeneration |
US20080038300A1 (en) * | 2005-05-13 | 2008-02-14 | Beiersdorf Ag | Self-Adhesive Skin Patch and Combination Set for Cosmetic Skin Care |
WO2009046819A2 (en) * | 2007-10-01 | 2009-04-16 | Beiersdorf Ag | Method for reducing signs of ageing on skin |
US20090110745A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20150713A1 (en) | 2012-10-09 | 2015-05-16 | Sigma Tau Ind Farmaceuti | MODIFIED HYALURONIC ACID DERIVATIVES AND THE USE OF THEM |
US9345659B2 (en) * | 2012-12-11 | 2016-05-24 | Avon Products, Inc. | Use of melicope extracts to improve conditions caused by excess lipids |
TW201422250A (en) * | 2012-12-11 | 2014-06-16 | Avon Prod Inc | Use of nesprin-2 expression modulators and compositions thereof |
WO2018067844A1 (en) | 2016-10-06 | 2018-04-12 | Mivi Neuroscience, Inc. | Hydraulic displacement and removal of thrombus clots, and catheters for performing hydraulic displacement |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994581A (en) * | 1998-03-09 | 1999-11-30 | Amt Labs, Inc. | Carnitine creatinate |
US20020044913A1 (en) * | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
US20020106388A1 (en) * | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
US6432424B1 (en) * | 2000-06-29 | 2002-08-13 | Johnson & Johnson Consumer Companies, Inc. | Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid |
US20030215506A1 (en) * | 2002-05-17 | 2003-11-20 | Kuhrts Eric H | Methods and compositions for enhancement of creatine transport |
US6653504B1 (en) * | 1999-09-03 | 2003-11-25 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Non-hygroscopic salts of active ingredients having therapeutical and/or nutritional activities and orally administrable compositions containing same |
US20040029969A1 (en) * | 2000-07-06 | 2004-02-12 | Beiersdorf Ag | Use of creatine or creatine derivatives in cosmetic or dematological preparations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2619007B1 (en) * | 1987-08-07 | 1990-09-28 | Dermatologiques Et | COSMETIC PREPARATIONS WITH LIPOLYTIC ACTION |
FR2694195B1 (en) | 1992-07-30 | 1994-09-23 | Sederma Sa | New slimming cosmetic compositions. |
JP4182183B2 (en) | 1999-08-24 | 2008-11-19 | ディーエスエム アイピー アセッツ ビー.ブイ. | Slimming skin cosmetics |
AU2001238511A1 (en) | 2000-08-07 | 2002-02-18 | Juvenon, Inc. | Cosmetics to support skin metabolism |
DE10056400A1 (en) * | 2000-11-14 | 2002-05-23 | Merck Patent Gmbh | Galenic formulation |
ITMI20030315A1 (en) * | 2003-02-21 | 2004-08-22 | Vama Farmacosmetica S R L | SALT OF CARNITINA, PRELIPOSOME CONTAINING IT AND DERMOCOSMETIC FORMULATION FOR TOPICAL USE BASED ON THE SAID CARNITINA SALT. |
-
2004
- 2004-12-21 US US11/018,901 patent/US20060134147A1/en not_active Abandoned
-
2005
- 2005-11-08 EP EP05826087A patent/EP1827360A4/en not_active Withdrawn
- 2005-11-08 WO PCT/US2005/040480 patent/WO2006068715A2/en active Application Filing
-
2007
- 2007-07-20 US US11/880,167 patent/US7763655B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994581A (en) * | 1998-03-09 | 1999-11-30 | Amt Labs, Inc. | Carnitine creatinate |
US6653504B1 (en) * | 1999-09-03 | 2003-11-25 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Non-hygroscopic salts of active ingredients having therapeutical and/or nutritional activities and orally administrable compositions containing same |
US20020044913A1 (en) * | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
US6432424B1 (en) * | 2000-06-29 | 2002-08-13 | Johnson & Johnson Consumer Companies, Inc. | Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid |
US20040029969A1 (en) * | 2000-07-06 | 2004-02-12 | Beiersdorf Ag | Use of creatine or creatine derivatives in cosmetic or dematological preparations |
US20020106388A1 (en) * | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
US20030215506A1 (en) * | 2002-05-17 | 2003-11-20 | Kuhrts Eric H | Methods and compositions for enhancement of creatine transport |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043312A1 (en) * | 2003-07-25 | 2005-02-24 | Shea Thomas B. | Formulations for reducing neuronal degeneration |
US8173618B2 (en) | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
US20080038300A1 (en) * | 2005-05-13 | 2008-02-14 | Beiersdorf Ag | Self-Adhesive Skin Patch and Combination Set for Cosmetic Skin Care |
US8101216B2 (en) | 2005-05-13 | 2012-01-24 | Beiersdorf Ag | Self-adhesive skin patch and combination set for cosmetic skin care |
WO2009046819A2 (en) * | 2007-10-01 | 2009-04-16 | Beiersdorf Ag | Method for reducing signs of ageing on skin |
WO2009046819A3 (en) * | 2007-10-01 | 2009-08-06 | Beiersdorf Ag | Method for reducing signs of ageing on skin |
US20090110745A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
US8597640B2 (en) | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
Also Published As
Publication number | Publication date |
---|---|
US20070264205A1 (en) | 2007-11-15 |
WO2006068715A2 (en) | 2006-06-29 |
EP1827360A2 (en) | 2007-09-05 |
US7763655B2 (en) | 2010-07-27 |
WO2006068715A3 (en) | 2006-11-23 |
EP1827360A4 (en) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7763655B2 (en) | Cosmetic compositions having carnitine creatinate and methods for using | |
US9750750B2 (en) | Compositions and methods for stimulating hair growth | |
EP2376198B1 (en) | A composition comprising a retinoid and method of treating skin conditions | |
JP5572318B2 (en) | Arginine heteromer for topical administration | |
US20180177703A1 (en) | Niacinamide Mononucleotide Formulations For Skin Aging | |
AU2010248292B2 (en) | Composition for preventing hair loss or for stimulating hair growth | |
JP2002255725A (en) | Treatment of skin | |
US20220183947A1 (en) | Cosmetic Compositions Comprising Sucrose Esters And Solvents | |
JP2023543917A (en) | Hair, scalp and skin treatment compositions | |
US12090223B2 (en) | Method of manufacturing cosmetic compositions comprising sucrose esters and solvents | |
KR101734801B1 (en) | Methods of reducing signs of skin aging using a combination of extracts | |
KR101734802B1 (en) | Topical composition including a combination of extracts for reducing signs of skin aging | |
US11020334B2 (en) | Compounds, compositions and use thereof | |
JPH08268866A (en) | Dermal preparation for external use | |
JP2000063255A (en) | Preparation for external use for skin | |
WO2024056566A1 (en) | Use of thioethylamine composition for skin rejuvenation and improved synergistic effect when combined with an organic acid and/or azabenzene-4-carboxamide | |
JPH10245393A (en) | Composition containing triterpenes | |
CN114727928A (en) | Composition for inducing and promoting change of environment around aged skin cells | |
WO2013180229A1 (en) | Composition for hair growth | |
CN113194910A (en) | Cosmetic composition for skin regeneration | |
JP2000256163A (en) | Skin lotion | |
JP2001199805A (en) | Antiseptic mildewproofing agent and composition for external use formulated with the same | |
JP2001122739A (en) | Hair tonic | |
JP2002114645A (en) | Hair tonic | |
JPH11279032A (en) | Antidandruff agent composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVON PRODUCTS INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KALAFSKY, ROBERT E.;REEL/FRAME:016117/0248 Effective date: 20041216 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |